All News

Found 320 articles

• Repare Therapeutics Expands Executive Leadership Team with the Appointment of Philip Herman as EVP Commercial & New Product Development

  1/5/2022

  Repare Therapeutics Inc. today announced the appointment of Philip Herman as its EVP Commercial & New Product Development.

• Y-mAbs Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

  1/5/2022

  Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that its Chief Executive Officer, Dr. Claus Moller, MD, Ph.D., will provide an overview and update on the Company's business at the virtual 40th Annual J.P. Morgan Healthcare Conference.

• FDA APPROVES TEZSPIRE™ (TEZEPELUMAB-EKKO) IN THE U.S. FOR SEVERE ASTHMA

  12/17/2021

  Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Amgen and AstraZeneca's Tezspire™ (tezepelumab-ekko) for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.

• Y-mAbs Announces Pipeline Update - Dec 15, 2021

  12/15/2021

  Y-mAbs Therapeutics, Inc. announced that clinical experience for naxitamab and data from the Company’s SADA technology programs will be presented at the Company’s R&D event, which will take place virtually today at 12 p.m. Eastern Time.

• UPDATE - Y-mAbs Announces Pipeline Update

  12/15/2021

  Y-mAbs Therapeutics, Inc. today announced that clinical experience for naxitamab and data from the Company’s SADA technology programs will be presented at the Company’s R&D event, which will take place virtually today at 12 p.m. Eastern Time.

• Ocuphire Expands Prestigious Medical Advisory Board with Six New KOLs to Support Advancement of Late-Stage Ophthalmic Assets Nyxol® and APX3330

  12/8/2021

  Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, announced that it has appointed six new key opinion leaders across retina, refractive surgery, and optometry to its Medical Advisory Board.

• Y-mAbs Hosting Virtual Research and Development Day

  12/6/2021

  Y-mAbs Therapeutics, Inc. a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced that it will host a virtual research and development day on Wednesday, December 15, 2021 at 12pm Eastern Time.

• Y-mAbs Announces Third Quarter Financial Results and Recent Corporate Developments

  11/4/2021

  Y-mAbs Therapeutics, Inc. a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, reported financial results for the third quarter of 2021.

• Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma CNS/LM Metastasis

  11/4/2021

  Y-mAbs Therapeutics, Inc. announced that, based on feedback from the U.S. Food and Drug Administration at a recent Type B meeting, where the Company provided the FDA with additional detailed data and the statistical analysis plan, the Company has requested a pre-BLA meeting for omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma.

• Genmab Announces Multiple Abstracts to be Presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH)

  11/4/2021

  Genmab Announces Multiple Abstracts to be Presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH)

• Sanofi : Strong Q3 performance drives guidance upgrade to around 14% business EPS growth at CER(1)

  10/28/2021

  Strong Q3 performance drives guidance upgrade to around 14% business EPS growth at CER

• Y-mAbs to Announce Third 2021 Financial and Operating Results on November 4, 2021

  10/28/2021

  Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended September 30, 2021 on Thursday, November 4, 2021, after the close of the U.S. financial markets.

• Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021

  10/19/2021

  Copenhagen, Denmark; October 19, 2021 – Genmab A/S announced that worldwide net trade sales of DARZALEX®,including sales of the subcutaneous formulation,as reported by Johnson & Johnson were USD 1,580million in the third quarter of 2021.

• Y-mAbs’ 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Granted Rare Pediatric Disease Designation by FDA

  10/7/2021

  Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB), today announced that the U.S. Food and Drug Administration (“FDA”) has granted Rare Pediatric Disease Designation (“RPDD”) for the Company’s lutetium labelled omburtamab antibody program for the treatment of medulloblastoma.

• Y-mAbs Announces Data to be Presented at SIOP 2021

  9/16/2021

  Y-mAbs Therapeutics, Inc. (“Y-mAbs”, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, is pleased to announce the acceptance of two presentations at the International Society of Pediatric Oncology (“SIOP”) Virtual Annual Congress held October 21 through October 24, 2021.

• Y-mAbs Announces Priority Review of BLA for DANYELZA® (naxitamab-gqgk) in China

  9/13/2021

  Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”), NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that its partner SciClone Pharmaceuticals (Holdings) Limited (“SciClone Pharmaceuticals”) has been granted priority review of the Biologics License Application (“BLA”) for DANYELZA® (naxitamab-gqgk).

• Y-mAbs to Host Key Opinion Leader Webinar on DANYELZA® (naxitamab-gqgk) Frontline and HITS Data in High-Risk Neuroblastoma

  9/10/2021

  Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB) today announced that it will host a key opinion leader ("KOL") webinar on DANYELZA frontline and HITS data in high-risk neuroblastoma on Thursday, September 23, 2021 at 12 p.m. ET.

• New Tezepelumab Data Show 86% Reduction In Exacerbations In Patients With Severe Asthma And Comorbid Nasal Polyps

  9/5/2021

  Amgen announced new data from the pivotal NAVIGATOR Phase 3 trial demonstrating that tezepelumab reduced exacerbations and improved lung function and nasal symptoms in patients with severe, uncontrolled asthma and comorbid nasal polyps.

• Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma

  8/30/2021

  Ligand Pharmaceuticals Incorporated today announced that its partner Gloria Biosciences (GloriaBio) has received approval from China’s National Medical Products Administration (NMPA) for zimberelimab (GLS-010), an OmniAb-derived anti-PD-1 monoclonal antibody for the treatment of recurrent or refractory classical Hodgkin’s lymphoma (cHL).

• WuXi Biologics Reports Strong 2021 Interim Results

  8/23/2021

  WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Company", together with its subsidiaries "the Group", stock code: 2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its unaudited interim results for the six months, ending on June 30, 2021.